{
    "name": "rabies immune globulin, human (RIG)",
    "comment": "Rx",
    "other_names": [
        "HyperRAB S/D",
        "KedRab",
        "Imogam Rabies HT",
        "RIG",
        "HyperRAB"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/hyperrab-s-d-kedrab-rabies-immune-globulin-human-righ-343142",
    "pregnancy": {
        "common": [
            "Has not been studied in pregnant women",
            "Animal and reproductive studies have not been conducted"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if excreted in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Patients who can document previous complete rabies pre-exposure prophylaxis or complete postexposure prophylaxis should only receive a booster rabies vaccine without RIG, owing to RIG interference with anamnestic response to the vaccine",
                "Hemolysis may occur, particularly in individuals at high risk (eg, thrombocytopenia, bleeding disorders)",
                "Monitor patients at increased risk of thrombosis or thrombotic complications for at least 24 hr",
                "Caution with prior allergic reactions to immune globulins (RIG contains small quantity of IgA)",
                "Avoid immunization with measles vaccine within 4 months after RIG; avoid other live attenuated vaccines for 3 months",
                "Do NOT give IV; do not inject into a blood vessel because of the risk of severe allergic or hypersensitivity reaction, including decreased blood pressure and anaphylactic shock",
                "A transient rise of the various passively transferred antibodies in the patientâ€™s blood may result in misleading positive results of serologic tests; passive transmission of antibodies to erythrocyte antigens (eg, A, B, and D), may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs test)",
                "RIG is derived from human plasma; therefore, the potential exists for viral transmission (eg, CJD)"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "rabies immune globulin, human (RIG), tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of BCG vaccine live by Other (see comment). Use Caution/Monitor. \nComment: High dose rabies immunoglobulin may impair response to active immunization."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of rabies immune globulin, human (RIG) by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of rabies vaccine by Other (see comment). Use Caution/Monitor. \nComment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of rabies vaccine chick embryo cell derived by Other (see comment). Use Caution/Monitor. \nComment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: High dose rabies immunoglobulin may impair response to active immunization."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "rabies immune globulin, human (RIG) decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor. Separate by 3 months."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of rabies immune globulin, human (RIG) by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site pain",
            "percent": "33"
        },
        {
            "name": "Headache",
            "percent": "15"
        },
        {
            "name": "Muscle pain",
            "percent": "9"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "9"
        },
        {
            "name": "Joint pain",
            "percent": "6"
        },
        {
            "name": "Dizziness",
            "percent": "6"
        },
        {
            "name": "Fatigue",
            "percent": "6"
        },
        {
            "name": "Abdominal pain",
            "percent": "4"
        },
        {
            "name": "Blood in urine",
            "percent": "4"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Feeling faint",
            "percent": "4"
        },
        {
            "name": "Bruising",
            "percent": "3"
        },
        {
            "name": "Sunburn",
            "percent": "3"
        },
        {
            "name": "WBCs in urine",
            "percent": "3"
        }
    ]
}